Prevalence

Global Cephalosporin Drug Market Forecast to Reach USD 21.9 Billion by 2029: Exceptional Growth in Bacterial Infection Treatments Fuels Market Expansion - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024

A sterling analysis of the global cephalosporin drug market has been conducted, encapsulating the various segments such as generation, route of administration, and application.

Key Points: 
  • A sterling analysis of the global cephalosporin drug market has been conducted, encapsulating the various segments such as generation, route of administration, and application.
  • This report delves into the current industry patterns, the comprehensive competitive landscape, and the elaborative market dynamics from 2019 to 2029.
  • Highlighting the significance of bacterial infections as a driving force behind the growth of the cephalosporin drug market, the report underscores the increasing global demand for effective antibiotics.
  • With a robust forecast predicting substantial growth, this report is an essential asset for those seeking to navigate the complex pathways of the cephalosporin drug market.

Global IV Catheters Market Insights Report 2023-2029: Peripheral Inserted Central Catheters (PICCs) Leading the Charge - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024

The global IV catheters market was valued at USD 4.93 billion in 2023 and is expected to reach a value of $6.64 billion by 2029, growing at a CAGR of 5.04%

Key Points: 
  • The global IV catheters market was valued at USD 4.93 billion in 2023 and is expected to reach a value of $6.64 billion by 2029, growing at a CAGR of 5.04%
    The global IV catheters market report contains exclusive data on 33 vendors.
  • BD, B Braun, Terumo, Teleflex, ICU Medical, and Nipro Medical are some leading players currently dominating the global IV catheters market.
  • The continuous growth in individuals with chronic conditions and the rapidly expanding elderly population are the primary factors fueling the global demand for peripheral IV catheters.
  • The peripheral inserted central catheters (PICCs) product segment accounted for the highest market share of over 45% of the global CIVCs market.

Global Parts Washer Market Outlook & Forecast 2024-2029: A Highly Competitive $1.9 Billion Industry with Ecoclean Group, Safety-Kleen Systems, and Cleaning Technologies Group Dominating - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024

The global parts washer market was valued at USD 1.40 billion in 2023 and is expected to reach $1.93 billion by 2029, growing at a CAGR of 5.51% from 2023-2029

Key Points: 
  • The global parts washer market was valued at USD 1.40 billion in 2023 and is expected to reach $1.93 billion by 2029, growing at a CAGR of 5.51% from 2023-2029
    The global parts washer market is highly competitive, with many vendors.
  • The key global parts washer market players are Ecoclean Group, Safety-Kleen Systems, and Cleaning Technologies Group.
  • APAC was the largest revenue contributor to the global parts washer market, accounting for a market share of over 43% in revenue in 2023.
  • The global parts washer market by washer type is segmented into a convery, drum washer, rotary basket washer, and cabinet washer.

Continuing Medical Education Market Report 2024: Substantial Growth Driven by Implementing Omnichannel Communication to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024

The "Global Continuing Medical Education Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Continuing Medical Education Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global continuing medical education (CME) market is embracing transformative growth, witnessing an anticipated compound annual growth rate (CAGR) of 7.70% between 2022 and 2028.
  • Emphasizing personalized experiences for healthcare professionals, omnichannel communication stands out as a pivotal trend in the CME landscape.
  • This innovative approach ensures that medical professionals have seamless access to critical information across multiple formats, contributing significantly to the market's steady climb.

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Retrieved on: 
Monday, February 26, 2024

Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.

Key Points: 
  • Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.
  • Additionally, a late-breaker oral presentation of Week 24 data from the INSIGHT trial evaluating Biktarvy in people with HIV and tuberculosis will be presented.
  • Gilead will present new data evaluating the safety and efficacy of Hepcludex® (bulevirtide) in people living with the coinfections of HIV, hepatitis B (HBV) and hepatitis delta (HDV).
  • Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone.

Global Central Vacuum System Market Outlook, 2023-2024 and 2029: Key Opportunities Driven by Growth in Demand for CVS with Hepa Filters and Smart Vaccum Systems - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024

The global central vacuum systems market is highly competitive, with many vendors.

Key Points: 
  • The global central vacuum systems market is highly competitive, with many vendors.
  • Some of the major players dominating the global central vacuum systems market include Trovac, DrainVac, Nuera Air, Nilfisk Group, and Busch.
  • In Europe, the demand for central vacuum systems is experiencing an increase, driven by stringent hygiene standards in the food processing industry and concerns about air quality, and dominated the global central vacuum systems market share, accounting for over 38% in 2023.
  • Furthermore, the growth of central vacuum systems in the APAC is attributed to the APAC's expansion of manufacturing and metalworking facilities.

GlobalData report highlights staggering $425.5 billion economic costs of obesity and overweight to U.S. Businesses and Employees in 2023

Retrieved on: 
Thursday, February 22, 2024

Obesity and overweight are estimated to have caused a staggering $425.5 billion in economic costs to U.S. businesses and employees in 2023, according to a report released by GlobalData Plc , a leading data and analytics company.

Key Points: 
  • Obesity and overweight are estimated to have caused a staggering $425.5 billion in economic costs to U.S. businesses and employees in 2023, according to a report released by GlobalData Plc , a leading data and analytics company.
  • Of the 158 million civilian employees on nonfarm payrolls, 30% (46.9M) are classified as having obesity and 34% (53.8M) have overweight.
  • Costs amounted to $347.5 billion attributed to obesity and $78 billion attributed to overweight.
  • Costs include $146.5 billion in higher medical costs for employees and their dependents, $82.3 billion in higher absenteeism (missed workdays), $160.3 billion in higher presenteeism (reduced productivity due to illness), $31.1 billion in higher disability costs, and $5.2 billion in higher Workers’ Compensation Program costs.

Brightside Health Expands Medicaid & Medicare Access for Greater Telemental Health Coverage

Retrieved on: 
Wednesday, February 21, 2024

Brightside Health today announced new and expanded payer partnerships to support Medicaid and Medicare.

Key Points: 
  • Brightside Health today announced new and expanded payer partnerships to support Medicaid and Medicare.
  • And among the 65 million Americans enrolled in Medicare, the Centers for Medicare & Medicaid Services reported that 25% experience mental illness .
  • “No mental health platform is complete without addressing the needs of Medicaid and Medicare beneficiaries, and these partnerships will provide access to life-saving mental health care for millions more people,” said Brad Kittredge, co-founder and CEO of Brightside Health.
  • “We are scaling quickly to ensure access to high-quality, measurably better mental health treatment.

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System

Retrieved on: 
Wednesday, February 21, 2024

The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), is a global coding system used to indicate a diagnosis for reimbursement purposes.

Key Points: 
  • The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), is a global coding system used to indicate a diagnosis for reimbursement purposes.
  • These codes are issued by the World Health Organization (WHO) and are used to show payers why a particular service was medically necessary.
  • The inclusion of NAFLD under the ICD-10 K76.0 code facilitates standardized billing for its diagnosis.
  • "This positive development is testament to the growing awareness of liver health and the intensifying need for effective diagnostic solutions.

Global Incretin Based Drugs Research Report 2023: Market Analysis by Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors - Market Insights and Forecasts 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 21, 2024

The "Global Incretin Based Drugs Market (2023 Edition): Analysis By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors), Route of Administration, By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Incretin Based Drugs Market (2023 Edition): Analysis By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors), Route of Administration, By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.
  • During the forecast period, 2024-2029, the Global Incretin Based Drugs market is expected to grow at a CAGR of 6.8%.
  • The Global Incretin Based Drugs Market is expected to generate USD 64.28 billion by the end of 2029, up from USD 40.72 Billion in 2022.
  • Global Incretin Based Drugs Market: Historic and Forecast (2018-2028)
    Estimated number of individuals with Diabetes Worldwide, in thousands (2000-2014E)
    Global Incretin Based Drugs Market: Market Value Assessment, 2018-2028 (USD Billion)
    Global Incretin-Based Drugs Market Segmentation: By Drug Type
    Global Incretin Based Drugs Market Size, By Glucagon-like Peptide-1 Receptor Agonists, By Value, 2018H-2028F (USD Billion & CAGR)
    Global Incretin Based Drugs Market Size, By Dipeptidyl Peptidase-4 Inhibitors, By Value, 2018H-2028F (USD Billion & CAGR)
    Global Incretin-Based Drugs Market Segmentation: By Route of Administration
    Global Incretin-Based Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
    Global Incretin-Based Drugs Market Size, By Injectables, By Value, 2018H-2028F (USD Billion & CAGR)
    Global Incretin Based Drugs Market Segmentation: By Indication
    Global Incretin Based Drugs Market, By Indication Overview
    Global Incretin Based Drugs Market Size, By Diabetes By Value, 2018H-2028F (USD Billion & CAGR)
    Global Incretin Based Drugs Market Size, By Obesity, By Value, 2018H-2028F (USD Billion & CAGR)